These trials have shown a reduction in atherosclerotic events with GLP-1 RAs, and for SGLT-2 inhibitors a reduction in hospitalisation for HF, adverse renal outcomes and all-cause mortality [9–18]. Here, GLP1R is linked to hydrops fetalis.